If you are not happy with the results below please do another search
Rhode Island on Jan. 25 reversed course and threw the state’s support behind a $21 billion nationwide settlement it originally declined to back resolving lawsuits alleging that three large drug distributors fueled the deadly U.S. opioid epidemic.
Early research suggesting that a popular non-psychoactive compound derived from marijuana might help prevent or treat COVID-19 warrants further investigation in rigorous clinical trials, researchers say.
Cellino Biotech announced a completed Series A financing of $80 million led by the impact investment arm of Bayer AG, Leaps by Bayer, 8VC, and Humboldt Fund and includes new investor Felicis Ventures.
Two cases of a subvariant of the Omicron variant were identified in Washington state. Two cases were also identified in Houston.
Johnson & Johnson on Jan. 25 forecast as much as $3.5 billion in sales of the company’s COVID-19 vaccine in 2022, a 46% jump for the shot that has fared poorly compared to rivals. Additionally, J&J plans to take a more aggressive stance on deals for the company’s medical device unit.
Sierra Oncology shared positive topline results from the company’s study on the effectiveness of momelotinib to treat patients with myelofibrosis.
Pfizer Inc. and BioNTech SE said on Jan. 25 they started a clinical trial to test a new version of their vaccine specifically designed to target the COVID-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen.
The U.S. health regulator revised on Jan. 24 the emergency use authorizations for COVID-19 antibody treatments from Regeneron and Eli Lilly to limit their use, as the drugs are unlikely to work against the Omicron coronavirus variant.
A New York judge struck down the state’s mask mandate on Jan. 24, one week before it was due to expire, ruling the governor overstepped her authority in imposing a rule that needed to have been passed by the state legislature.
The U.S. Food and Drug Administration granted Emergency Use Authorization for Mammoth Biosciences Inc.’s DETECTR BOOST SARS-CoV-2 Reagent Kit, a first of its kind high-throughput solution that combines the power of CRISPR with laboratory automation for SARS-CoV-2 testing.